TW202146004A - 用以治療子宮頸細胞異常的組合物 - Google Patents

用以治療子宮頸細胞異常的組合物 Download PDF

Info

Publication number
TW202146004A
TW202146004A TW110105956A TW110105956A TW202146004A TW 202146004 A TW202146004 A TW 202146004A TW 110105956 A TW110105956 A TW 110105956A TW 110105956 A TW110105956 A TW 110105956A TW 202146004 A TW202146004 A TW 202146004A
Authority
TW
Taiwan
Prior art keywords
asc
change
pharmaceutical composition
acid
composition
Prior art date
Application number
TW110105956A
Other languages
English (en)
Chinese (zh)
Inventor
諾博 傅科斯
Original Assignee
奧地利商賽羅醫學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 奧地利商賽羅醫學有限公司 filed Critical 奧地利商賽羅醫學有限公司
Publication of TW202146004A publication Critical patent/TW202146004A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110105956A 2020-03-03 2021-02-20 用以治療子宮頸細胞異常的組合物 TW202146004A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20160817.1 2020-03-03
EP20160817.1A EP3875083A1 (en) 2020-03-03 2020-03-03 Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid

Publications (1)

Publication Number Publication Date
TW202146004A true TW202146004A (zh) 2021-12-16

Family

ID=69770560

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110105956A TW202146004A (zh) 2020-03-03 2021-02-20 用以治療子宮頸細胞異常的組合物

Country Status (23)

Country Link
US (1) US20230092142A1 (cg-RX-API-DMAC7.html)
EP (2) EP3875083A1 (cg-RX-API-DMAC7.html)
JP (1) JP7840859B2 (cg-RX-API-DMAC7.html)
CN (1) CN115279358A (cg-RX-API-DMAC7.html)
AR (1) AR122387A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021231205B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022017436A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022002363A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126764T1 (cg-RX-API-DMAC7.html)
ES (1) ES2976058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240374T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066384T2 (cg-RX-API-DMAC7.html)
IL (1) IL296146A (cg-RX-API-DMAC7.html)
MA (1) MA58262B1 (cg-RX-API-DMAC7.html)
MD (1) MD4084788T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022010838A (cg-RX-API-DMAC7.html)
PL (1) PL4084788T3 (cg-RX-API-DMAC7.html)
RS (1) RS65349B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400126T1 (cg-RX-API-DMAC7.html)
TW (1) TW202146004A (cg-RX-API-DMAC7.html)
UA (1) UA130108C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021175877A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208848B (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406377C (en) 2000-05-10 2010-07-06 Okopharm Forschungs-Und Entwicklungs-Gmbh Method for reducing the surface area of silicon dioxide
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412703B (de) 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung
AT511159A1 (de) * 2011-02-16 2012-09-15 Selo Medical Gmbh Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
EP3616693A1 (en) * 2018-08-28 2020-03-04 Selo Medical GmbH Therapy of high-risk human papillomavirus infections

Also Published As

Publication number Publication date
JP2023516153A (ja) 2023-04-18
EP3875083A1 (en) 2021-09-08
MD4084788T2 (ro) 2024-06-30
BR112022017436A2 (pt) 2022-10-18
HUE066384T2 (hu) 2024-07-28
PL4084788T3 (pl) 2024-06-03
UA130108C2 (uk) 2025-11-12
EP4084788B1 (en) 2024-02-14
CL2022002363A1 (es) 2023-03-31
ZA202208848B (en) 2024-09-25
ES2976058T3 (es) 2024-07-22
AU2021231205A1 (en) 2022-09-01
MX2022010838A (es) 2022-09-27
CY1126764T1 (el) 2026-02-25
MA58262B1 (fr) 2024-03-29
WO2021175877A1 (en) 2021-09-10
CN115279358A (zh) 2022-11-01
RS65349B1 (sr) 2024-04-30
SMT202400126T1 (it) 2024-05-14
AR122387A1 (es) 2022-09-07
EP4084788A1 (en) 2022-11-09
HRP20240374T1 (hr) 2024-06-07
JP7840859B2 (ja) 2026-04-06
AU2021231205B2 (en) 2026-02-26
EP4084788C0 (en) 2024-02-14
CA3167015A1 (en) 2021-09-10
US20230092142A1 (en) 2023-03-23
IL296146A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
US20250281524A1 (en) Therapy of high-risk human papillomavirus infections
Tay Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study
CN107582563B (zh) 用于治疗子宫颈非典型性增生或子宫颈癌的包含亚硒酸盐或含亚硒酸盐化合物的药物制剂
EP4084788B1 (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
CA3167015C (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
EA048159B1 (ru) Композиция для применения в лечении аномалий цервикальных клеток, содержащая селенитовое соединение и кислоту
HK40074763A (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
HK40074763B (en) Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
Vázquez‐Martínez et al. Human papillomavirus type 2 associated with pyogenic granuloma in patients without clinical evidence of warts
HK40045218A (en) Therapy of high-risk human papillomavirus infections
HK40045218B (en) Therapy of high-risk human papillomavirus infections
EA042677B1 (ru) Терапия папилломавирусных инфекций человека высокого риска
EA048333B1 (ru) Терапия папилломавирусных инфекций человека высокого риска